NDLI: Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria

Content Provider	Springer Nature Link
Author	Reiner Concin, A. Regitnig, P. Dinges, H. P. Höfler, G. Lax, S. Müller Holzner, E. Obrist, P. Rudas, M.
Copyright Year	2008
Abstract	Practice and accuracy of immunohistochemistry is known to vary highly. Reliability of HER-2 immunohistochemistry is critical because of its role in patient selection for therapeutical options in breast cancer. Therefore reliability of HER-2 immunohistochemistry in pathology laboratories in Austria was assessed. Ten tissue specimens of invasive ductal breast carcinomas and three cell line samples were tested. Presence/absence of gene amplification was determined by FISH to be used as a gold standard. Laboratories were asked to stain and assess slides using their routine immunohistochemical staining protocol. Overall the study consisted of 311 tests on tissue specimens and 142 on cell lines. In all cases manual scoring was performed. Participation was voluntary and was 94%. Overall sensitivity was 90.5% and specificity 99.2%. Overscoring including true false positive results were found in 6.7% and 6.3% in tissue specimens and cell lines, respectively. False negative determinations were obtained in 1.9% and 2.8% of tissue specimens and cell lines, respectively. HercepTest$^{TM}$ showed slightly higher reliability in comparison with individualized staining methods. By manual scoring inaccurate scoring affected 12.3% of test results and 62% of the laboratories. In conclusion participation rate and accuracy of HER-immunohistochemistry was high all over the country. Manually performed scoring demonstrated some limitations.
Starting Page	253
Ending Page	259
Page Count	7
File Format	PDF
ISSN	12194956
Journal	Pathology & Oncology Research
Volume Number	14
Issue Number	3
e-ISSN	15322807
Language	English
Publisher	Springer Netherlands
Publisher Date	2008-08-28
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Breast cancer HER-2 Immunohistochemistry Quality assurance Reproducibility Biomedicine general Immunology Pathology Oncology Cancer Research
Content Type	Text
Resource Type	Article
Subject	Cancer Research Pathology and Forensic Medicine Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.

Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma

Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients

HER-2, TOP2A and chromosome 17 alterations in breast cancer

HER-2/neu genotype of breast cancer may change in bone metastasis

Expression of Ephb2 and Ephb4 in breast carcinoma

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH results

Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry

Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria

Similar Documents

Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.

Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma

Clinical findings and HER-2/neu gene amplification status of breast carcinoma patients

HER-2, TOP2A and chromosome 17 alterations in breast cancer

HER-2/neu genotype of breast cancer may change in bone metastasis

Expression of Ephb2 and Ephb4 in breast carcinoma

Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations

Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR — A comparison with immunohistochemical and FISH results

Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry

Practice of HER-2 Immunohistochemistry in Breast Carcinoma in Austria